Abstract 161P
Background
Targeted therapy and Immunotherapy have revolutionized the treatment of metastatic non-small cell lung cancer (NSCLC), particularly adenocarcinoma (AC). Among NSCLC cases, around 8-10% are ALK positive with the majority involving EML4-ALK gene variants. This study aims to explore the connection between ALK gene variants and PDL1 expression in metastatic lung AC, as there is limited data from the Indian cohort on this subject.
Methods
A retrospective analysis was conducted on data collected from 17 advanced lung AC patients with ALK gene mutations. The ALK protein variants were determined through Next-Generation Sequencing, while PDL1 expression was assessed using Immunohistochemistry with sP263 antibody. These findings were then correlated with relevant clinical parameters.
Results
The median age of the patient cohort was 46 years (range 28 to 65). Among the 17 ALK-positive, the majority had EML4-ALK gene fusions, with V1 (47.05%), V3 (35.2%), and V2 (11.7%) being the most common variants. V1 was more prevalent in females (87.5%) than males (12.5%). PDL1 negativity was observed in 64.7% of patients, while 35.2% were PDL1 positive. Specifically, PDL1 negativity was more common in the V1 variant, whereas PDL1 positivity was associated with V3. Brain metastases were more frequent in the PDL1-negative cohort (35.2%), and bone metastases and malignant pleural effusions were more common in V1 compared to V2 and V3. Table: 161P
ALK metastatic sites | Frequency |
Malignant pleural effusion | 70.5% |
Brain metastasis | 35.2% |
Bone metastasis | 35.2% |
Contralateral lung involvement | 23.5% |
Liver metastasis | 11.7% |
Conclusions
The study concludes that V1 and V3 EML4-ALK gene variants are prevalent in metastatic lung AC patients. It reveals a significant association between PDL1 expression and specific ALK variants, with V1 being more frequently associated with PDL1 negativity and V3 with PDL1 positivity. Additionally, the V1 and V3 variants were more commonly found in female patients and were associated with brain metastases. This real-world experience contributes valuable insights into treatment responses in this specific patient population.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
113P - Evaluation of effects of tissue preservation methods on the proteome abundance through deep proteomics of breast cancer tissue
Presenter: Shashwati parihari
Session: Cocktail & Poster Display session
Resources:
Abstract
114P - Circulating microRNAs and response to oncological and surgical therapy in patients with locally advanced gastric cancer
Presenter: Vasileia Kokala-Dimitropoulou
Session: Cocktail & Poster Display session
Resources:
Abstract
115P - BrainStorm-NSE: Serum neuron-specific enolase as a biomarker for central nervous system metastases: A prospective cohort study
Presenter: Diogo Martins-Branco
Session: Cocktail & Poster Display session
Resources:
Abstract
116P - Switching to a multigenic parallel sequencing approach: The landscape of biomarkers profiling changing between immunohistochemistry and next generation sequencing advantages and sustainability from a public hospital in Northern Italy
Presenter: Giulia Ghirardi
Session: Cocktail & Poster Display session
Resources:
Abstract
117P - Homologous recombination deficiency (HRD) by shallow whole genome sequencing (sWGS): Seamless integration in an existing NGS somatic oncology workflow
Presenter: Etienne Muller
Session: Cocktail & Poster Display session
Resources:
Abstract
118P - Molecular diagnostics of gastrointestinal stromal tumors in the era of precision oncology
Presenter: Alena Kalfusova
Session: Cocktail & Poster Display session
Resources:
Abstract
119P - De novo and histologically transformed small-cell lung cancer is sensitive to lurbinectedin treatment through the modulation of EMT and NOTCH signaling pathways
Presenter: Triparna Sen
Session: Cocktail & Poster Display session
Resources:
Abstract
120P - Anti-angiogenic therapy or immunotherapy? A multicenter real-world study of patients with advanced non-small cell lung cancer with EGFR / HER2 exon 20 insertion mutations
Presenter: Tianqing Chu
Session: Cocktail & Poster Display session
Resources:
Abstract
121P - Clinical outcomes of compound EGFR mutation in non-small cell lung cancer: A national, retrospective, multicenter study
Presenter: Aurélien Brindel
Session: Cocktail & Poster Display session
Resources:
Abstract
122P - Molecular testing, treatment, and response of patients with advanced solid tumors harboring an NTRK gene fusion: Second interim results of the REALTRK registry
Presenter: Sebastian Lange
Session: Cocktail & Poster Display session
Resources:
Abstract